Photo by nci from unsplash
2577Background: Mutant isocitrate dehydrogenase 1 (mIDH1) produces the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO; AG-120) is a targeted mIDH1 inhibitor under evaluation in an ongo... Click to show full abstract
2577Background: Mutant isocitrate dehydrogenase 1 (mIDH1) produces the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO; AG-120) is a targeted mIDH1 inhibitor under evaluation in an ongo...
Keywords:
pharmacodynamics ivosidenib;
ivosidenib patients;
patients idh1;
mutant advanced;
pharmacokinetics pharmacodynamics;
idh1 mutant
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!